
immatics biotechnologies GmbH – NASDAQ:IMTXW
immatics biotechnologies GmbH stock price today
immatics biotechnologies GmbH stock price monthly change
immatics biotechnologies GmbH stock price quarterly change
immatics biotechnologies GmbH stock price yearly change
immatics biotechnologies GmbH key metrics
Market Cap | 635.91M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.98 |
Revenue | 74.64M |
EBITDA | -68.81M |
Income | -80.31M |
Revenue Q/Q | 210.81% |
Revenue Y/Y | -6.36% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -92.18% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeimmatics biotechnologies GmbH stock price history
immatics biotechnologies GmbH stock forecast
immatics biotechnologies GmbH financial statements
Jun 2023 | 22.35M | -24.61M | -110.09% |
---|---|---|---|
Sep 2023 | 5.92M | -26.48M | -447% |
Dec 2023 | 15.92M | -26.14M | -164.24% |
Mar 2024 | 30.44M | -3.07M | -10.09% |
Jun 2023 | 410189000 | 191.97M | 46.8% |
---|---|---|---|
Sep 2023 | 437450000 | 189.69M | 43.36% |
Dec 2023 | 509965000 | 284.88M | 55.86% |
Mar 2024 | 653730305 | 252.57M | 38.64% |
Jun 2023 | -6.60M | -16.83M | 36.45M |
---|---|---|---|
Sep 2023 | -30.52M | -70.57M | 49.90M |
Dec 2023 | 79.07M | 59.73M | -972K |
Mar 2024 | -32.79M | -243.24M | 175.67M |
immatics biotechnologies GmbH alternative data
Jan 2024 | 433 |
---|---|
Feb 2024 | 433 |
Mar 2024 | 432 |
Apr 2024 | 432 |
May 2024 | 432 |
Jun 2024 | 432 |
Jul 2024 | 432 |
immatics biotechnologies GmbH other data
Patent |
---|
Application Filling date: 13 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 3 Mar 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 18 Mar 2022 Issue date: 6 Sep 2022 |
Grant Utility: Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods Filling date: 24 Sep 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 27 Aug 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 5 Dec 2019 Issue date: 6 Sep 2022 |
Application Filling date: 2 May 2022 Issue date: 1 Sep 2022 |
Grant Utility: Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers Filling date: 11 Feb 2022 Issue date: 30 Aug 2022 |
Grant Filling date: 10 Apr 2018 Issue date: 30 Aug 2022 |
Application IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS Filling date: 6 May 2022 Issue date: 25 Aug 2022 |
-
What's the price of immatics biotechnologies GmbH stock today?
One share of immatics biotechnologies GmbH stock can currently be purchased for approximately $0.
-
When is immatics biotechnologies GmbH's next earnings date?
Unfortunately, immatics biotechnologies GmbH's (IMTXW) next earnings date is currently unknown.
-
Does immatics biotechnologies GmbH pay dividends?
No, immatics biotechnologies GmbH does not pay dividends.
-
How much money does immatics biotechnologies GmbH make?
immatics biotechnologies GmbH has a market capitalization of 635.91M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 68.76% to 54M US dollars.
-
What is immatics biotechnologies GmbH's stock symbol?
immatics biotechnologies GmbH is traded on the NASDAQ under the ticker symbol "IMTXW".
-
What is immatics biotechnologies GmbH's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of immatics biotechnologies GmbH?
Shares of immatics biotechnologies GmbH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does immatics biotechnologies GmbH have?
As Jul 2024, immatics biotechnologies GmbH employs 432 workers.
-
When immatics biotechnologies GmbH went public?
immatics biotechnologies GmbH is publicly traded company for more then 5 years since IPO on 2 Jul 2020.
-
What is immatics biotechnologies GmbH's official website?
The official website for immatics biotechnologies GmbH is immatics.com.
-
How can i contact immatics biotechnologies GmbH?
immatics biotechnologies GmbH can be reached via phone at +49 7071 53970.
immatics biotechnologies GmbH company profile:

immatics biotechnologies GmbH
immatics.comNASDAQ
542
Biotechnology
Healthcare
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Tübingen, 72076
CIK: 0001809196
ISIN: NL0015285958
CUSIP: N44445117